Skip to main content
Log in

New insights on interactions between HIV-1 and HSV-2

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Herpes simplex type 2 (HSV-2) infection is common and frequently asymptomatic. Concerns exist about the high prevalence of HSV-2, particularly in areas of high HIV prevalence, because of observations that HSV-2 is associated with an increased risk of HIV acquisition, transmission, and disease progression. Several randomized trials have tested or are testing whether HSV-2 treatment can limit the spread of HIV, with mixed results. Although treatment with acyclovir, 400 mg twice daily, does not reduce HIV incidence, suppressive acyclovir and valacyclovir reduce HIV levels in plasma and in the genital tract. Ongoing trials are evaluating whether HSV suppression will reduce HIV transmission and disease progression. Until a protective HSV-2 or HIV vaccine is available, effective interventions that reduce the effect of HSV-2 on HIV transmission are critically needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86:805–812, A.

    Article  PubMed  Google Scholar 

  2. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al.: Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000, 182:1090–1096.

    Article  PubMed  CAS  Google Scholar 

  3. Safrin S, Ashley R, Houlihan C, et al.: Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS 1991, 5:1107–1110.

    Article  PubMed  CAS  Google Scholar 

  4. Siegal FP, Lopez C, Hammer GS, et al.: Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981, 305:1439–1444.

    PubMed  CAS  Google Scholar 

  5. Langenberg A, Benedetti J, Jenkins J, et al.: Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic” herpes simplex virus type 2 infection. Ann Intern Med 1989, 110:882–887.

    PubMed  CAS  Google Scholar 

  6. Frenkel LM, Garratty EM, Shen JP, et al.: Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993, 118:414–418.

    PubMed  CAS  Google Scholar 

  7. Celum C, Wald A, Hughes J, et al.: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109–2119.

    Article  PubMed  CAS  Google Scholar 

  8. Wald A, Zeh J, Selke S, et al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000, 342:844–850.

    Article  PubMed  CAS  Google Scholar 

  9. Kamali A, Nunn AJ, Mulder DW, et al.: Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect 1999, 75:98–102.

    Article  PubMed  CAS  Google Scholar 

  10. McFarland W, Gwanzura L, Bassett MT, et al.: Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999, 180:1459–1465.

    Article  PubMed  CAS  Google Scholar 

  11. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004, 35:435–445.

    Article  PubMed  Google Scholar 

  12. Freeman EE, Weiss HA, Glynn JR, et al.: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20:73–83.

    Article  PubMed  Google Scholar 

  13. Brown JM, Wald A, Hubbard A, et al.: Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007, 21:1515–1523.

    Article  PubMed  Google Scholar 

  14. Koelle DM, Abbo H, Peck A, et al.: Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994, 169:956–961.

    PubMed  CAS  Google Scholar 

  15. Rebbapragada A, Wachihi C, Pettengell C, et al.: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007, 21:589–598.

    Article  PubMed  Google Scholar 

  16. Zhu J, Koelle DM, Cao J, et al.: Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007, 204:595–603.

    Article  PubMed  CAS  Google Scholar 

  17. Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560–1571.

    Article  PubMed  CAS  Google Scholar 

  18. Mark KE, Wald A, Magaret AS, et al.: Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008, 198:1141–1149.

    Article  PubMed  Google Scholar 

  19. Posavad CM, Wald A, Kuntz S, et al.: Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004, 190:693–696.

    Article  PubMed  Google Scholar 

  20. Strick LB, Wald A, Celum C: Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006, 43:347–356.

    Article  PubMed  Google Scholar 

  21. Schacker T, Ryncarz AJ, Goddard J, et al.: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280:61–66.

    Article  PubMed  CAS  Google Scholar 

  22. Mole L, Ripich S, Margolis D, Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766–770.

    Article  PubMed  CAS  Google Scholar 

  23. McClelland RS, Wang CC, Overbaugh J, et al.: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002, 16:2425–2430.

    Article  PubMed  Google Scholar 

  24. Diaz JJ, Dodon MD, Schaerer-Uthurralt N, et al.: Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996, 379:273–277.

    Article  PubMed  CAS  Google Scholar 

  25. Margolis DM, Rabson AB, Straus SE, Ostrove JM: Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992, 186:788–791.

    Article  PubMed  CAS  Google Scholar 

  26. Mosca JD, Bednarik DP, Raj NB, et al.: Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987, 325:67–70.

    Article  PubMed  CAS  Google Scholar 

  27. Heng MC, Heng SY, Allen SG: Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994, 343:255–258.

    Article  PubMed  CAS  Google Scholar 

  28. Kucera LS, Leake E, Iyer N, et al.: Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990, 6:641–647.

    Article  PubMed  CAS  Google Scholar 

  29. Clouse KA, Powell D, Washington I, et al.: Monokine regulation of human immune deficiency virus type 1 expression in a chronically infected human t-cell line. J Immunol 1989, 142:431–438.

    PubMed  CAS  Google Scholar 

  30. Paludan SR: Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J Virol 2001, 75:8008–8015.

    Article  PubMed  CAS  Google Scholar 

  31. LeGoff J, Weiss HA, Gresenguet G, et al.: Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007, 21:1569–1578.

    Article  PubMed  Google Scholar 

  32. Paz-Bailey G, Sternberg M, Puren A, et al.: Impact of episodic acyclovir therapy on genital ulcer duration and HIV shedding from herpetic ulcers among men in South Africa. Presented at the 17th International Society for Sexually Transmitted Diseases Research Conference. Seattle, WA; July 30–August 1, 2007.

  33. Zuckerman RA, Lucchetti A, Whittington WL, et al.: Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007, 196:1500–1508.

    Article  PubMed  CAS  Google Scholar 

  34. Baeten JM, Strick LB, Lucchetti A, et al.: Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008, 198:1804–1808.

    Article  PubMed  CAS  Google Scholar 

  35. Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790–799.

    Article  PubMed  CAS  Google Scholar 

  36. Dunne EF, Whitehead S, Sternberg M, et al.: Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008, 49:77–83.

    Article  PubMed  CAS  Google Scholar 

  37. Delany S, Clayton T, Mlaba N, et al.: Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 coinfected women: a randomised placebo-controlled trial in South Africa. AIDS 2008, in press.

  38. Cowan FM, Pascoe SJ, Barlow KL, et al.: A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008, 84:548–553.

    Article  PubMed  CAS  Google Scholar 

  39. Lingappa JR, Lambdin B, Bukusi EA, et al.: Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 2008, 3:e1411.

    Article  Google Scholar 

  40. Ameli N, Bacchetti P, Morrow RA, et al.: Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006, 20:1051–1058.

    Article  PubMed  Google Scholar 

  41. Ouedraogo A, Nagot N, Vergne L, et al.: Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006, 20:2305–2313.

    Article  PubMed  CAS  Google Scholar 

  42. Lisco A, Vanpouille C, Tchesnokov EP, et al.: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008, 4:260–270.

    Article  PubMed  CAS  Google Scholar 

  43. McMahon MA, Siliciano JD, Lai J, et al.: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008, 283:31289–31293.

    Article  PubMed  CAS  Google Scholar 

  44. Cowan FM, Humphrey JH, Ntozini R, et al.: Maternal herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 2008, 22:193–201.

    Article  PubMed  Google Scholar 

  45. Bollen LJ, Whitehead SJ, Mock PA, et al.: Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 2008, 22:1169–1176.

    Article  PubMed  Google Scholar 

  46. Drake AL, John-Stewart GC, Wald A, et al.: Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007, 109(2 Pt 1):403–409.

    Google Scholar 

  47. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946–954.

    PubMed  CAS  Google Scholar 

  48. Ioannidis JP, Collier AC, Cooper DA, et al.: Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998, 178:349–359.

    PubMed  CAS  Google Scholar 

  49. Smith MS, Thresher RJ, Pagano JS: Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob Agents Chemother 1991, 35:62–67.

    PubMed  CAS  Google Scholar 

  50. Modjarrad K, Chamot E, Vermund SH: Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008, 22:2179–2185.

    Article  PubMed  CAS  Google Scholar 

  51. Nagot N, Ouedraogo A, Konate I, et al.: Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008, 198:241–249.

    Article  PubMed  CAS  Google Scholar 

  52. Reyes M, Shaik NS, Graber JM, et al.: Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003, 163:76–80.

    Article  PubMed  Google Scholar 

  53. Gupta R, Hill EL, McClernon D, et al.: Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J Infect Dis 2005, 192:1102–1107.

    Article  PubMed  CAS  Google Scholar 

  54. Swetter SM, Hill EL, Kern ER, et al.: Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis 1998, 177:543–550.

    PubMed  CAS  Google Scholar 

  55. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al.: PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006, 193:27–35.

    Article  PubMed  CAS  Google Scholar 

  56. Bailey RC, Moses S, Parker CB, et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007, 369:643–656.

    Article  PubMed  Google Scholar 

  57. Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007, 369:657–666.

    Article  PubMed  Google Scholar 

  58. Tobian A, Serwadda D, Quinn T, et al.: Trial of male circumcision: prevention of HSV-2 in men and vaginal infections in female partners, Rakai, Uganda. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sinéad Delany-Moretlwe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delany-Moretlwe, S., Lingappa, J.R. & Celum, C. New insights on interactions between HIV-1 and HSV-2. Curr Infect Dis Rep 11, 135–142 (2009). https://doi.org/10.1007/s11908-009-0020-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-009-0020-8

Keywords

Navigation